Hypercoagulable states and thrombophilia
Starts from the event (DVT/PE by provocation, unusual-site venous thrombosis, arterial thrombosis at a young age, pregnancy morbidity, family screening) and the clues to a hypercoagulable state (recurrence, family history, warfarin skin necrosis, heparin resistance, thrombocytopenia, haemolysis, raised blood counts, autoimmune disease, prolonged aPTT) to say whether thrombophilia testing helps (ASH 2023, BSH 2022). Lists the tests and their timing, including the effect of acute thrombosis, heparin, warfarin and DOACs on antithrombin, protein C and S and lupus anticoagulant. Classifies the results as antiphospholipid syndrome (single, double or triple positive, persistent at 12 weeks), high-risk inherited thrombophilia, low-risk heterozygous FVL or prothrombin, MPN or PNH, and chooses the anticoagulant: VKA for APS (DOACs contraindicated in triple-positive or arterial APS), mechanical valves, end-stage kidney disease and interacting drugs; a DOAC for inherited thrombophilia; LMWH in pregnancy; non-heparin drugs in HIT. Sets the duration of anticoagulation, contraception and pregnancy prophylaxis.
- Unprovoked VTE: indefinite anticoagulation is already suggestedASH 2023 · ESC 2019 PETesting for inherited thrombophilia rarely changes management; test for antiphospholipid antibodies, because APS changes the drug (VKA, not a DOAC).
- A DOAC is suitable (apixaban, rivaroxaban, edoxaban, dabigatran)IESC 2019 PE · ASH 2020Inherited thrombophilia or no thrombophilia: DOACs were as effective as warfarin in trial subgroups with FVL, prothrombin, protein C/S and antithrombin defects, with less major bleeding.
- Unprovoked VTE: extended anticoagulation of indefinite duration should be consideredIIaESC 2019 PEReview bleeding risk every year; reduced-dose apixaban or rivaroxaban after 6 months.
- Contraception and pregnancyASH 2018 pregnancy · ASH 2023Avoid oestrogen-containing contraception and HRT; progestogen-only pill, implant or levonorgestrel IUD instead. Antepartum and postpartum LMWH prophylaxis with a high-risk thrombophilia or previous VTE; postpartum for 6 weeks with heterozygous FVL/prothrombin and a family history.
- Antiphospholipid antibodiesISTH 2020 · ACR/EULAR 2023Lupus anticoagulant (dRVVT and an LA-sensitive aPTT), anticardiolipin IgG/IgM and anti-β2-glycoprotein I IgG/IgM (ELISA). Positive = LA, or medium–high titre (> 40 units, > 99th centile). Repeat after ≥ 12 weeks to confirm persistence.
- Inherited thrombophilia panelBSH 2022Factor V Leiden and prothrombin G20210A (genetic: valid at any time, on any anticoagulant). Antithrombin activity, protein C activity and free protein S antigen (functional assays: affected by the drug and the clot).
- Not usefulIIIASH 2023 · BSH 2022MTHFR polymorphisms, homocysteine for VTE decisions, factor VIII, PAI-1 and other gene panels.
- When to testBSH 2022Ideally ≥ 3 months after the event, when the decision to stop or continue is due. Not during acute thrombosis: antithrombin, protein C and S fall and antiphospholipid tests can be transiently positive. Avoid in pregnancy (protein S falls) and on oestrogen.
| VKA (warfarin, INR 2–3) | Antiphospholipid syndrome (always if triple positive or arterial), mechanical valve, moderate–severe rheumatic MS with AF, CrCl < 15 mL/min or dialysis, strong interacting drugs, breastfeeding, cost |
| DOAC | Inherited thrombophilia (FVL, prothrombin, protein C/S, antithrombin deficiency), no thrombophilia, cancer-associated VTE (apixaban, edoxaban, rivaroxaban), weight > 120 kg (apixaban, rivaroxaban) |
| LMWH | Pregnancy, recurrence on a VKA or DOAC despite adherence, cancer with high GI/GU bleeding risk, the first days before warfarin reaches INR ≥ 2 |
| Non-heparin | Heparin-induced thrombocytopenia: argatroban, bivalirudin, fondaparinux or a DOAC |
- Middeldorp S, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv 2023;7:7101-7138.
- Arachchillage DJ, et al. Thrombophilia testing: a British Society for Haematology guideline. Br J Haematol 2022;198:443-458.
- Tektonidou MG, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296-1304.
- Barbhaiya M, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 2023;75:1687-1702.
- Cohen H, et al. Guidance on the use of direct oral anticoagulants in patients with antiphospholipid syndrome (ISTH SSC). J Thromb Haemost 2020;18:2126-2137.
- Pengo V, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). Blood 2018;132:1365-1371.
- Devreese KMJ, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the ISTH: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020;18:2828-2839.
- Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J 2020;41:543-603.
- Ortel TL, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020;4:4693-4738.
- Cuker A, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018;2:3360-3392.
- Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018;2:3317-3359.
- Martin KA, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC. J Thromb Haemost 2021;19:1874-1882.